$130.4m market cap
$1.71 last close
Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for chronic liver disease. The company’s lead asset is CRV431, a cyclophilin inhibitor being developed for the treatment of non-alcoholic steatohepatitis (NASH).
Investment summary
Despite a challenging operating environment due to COVID-19, Hepion was able to advance its CRV431 development program (for the treatment of non-alcoholic steatohepatitis, NASH) without major disruption, despite widespread issues for many companies in enrolling clinical studies. The company completed Phase I testing during 2020 and initiated a Phase IIa study that is nearing completion (Q221).
Y/E Dec |
Revenue (US$m) |
EBITDA (US$m) |
PBT (US$m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2019A | 0.0 | (7.7) | (7.9) | (341.55) | N/A | N/A |
| 2020A | 0.0 | (17.7) | (17.9) | (185.69) | N/A | N/A |
| 2021E | 0.0 | (19.6) | (19.6) | (25.69) | N/A | N/A |
| 2022E | 0.0 | (17.0) | (17.0) | (21.26) | N/A | N/A |
Industry outlook
There currently are no approved medications for NASH, but a large number of programs in development. Fatty liver disease affects 20% of US and European populations and 20% of these are expected to progress to NASH. We expect CRV431 to be marketed for severe cases (F2 and F4), which we estimate has a market of 1.4 million in the US and Europe.
Last updated on 13/04/2021
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (US$m) | 102.2 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Robert Foster | CEO |
| John Cavan | FD |
